Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC – NEW ENGLAND JOURNAL OF MEDICINE

Lu, S; Kato, T; Dong, XR; Ahn, MJ; Quang, L; Soparattanapaisarn, N; Inoue, T; Wang, CL; Huang, MJ; Yang, JCH; Cobo, M; Özgüroglu, M; Casarini, I; Khiem, DV; Sriuranpong, V; Cronemberger, E; Takahashi, T; Runglodvatana, Y; Chen, M; Huang, XN; Grainger, E; Ghiorghiu, D; van der Gronde, T; Ramalingam, SS – 2024 – 10.1056/NEJMoa2402614